Adicet Bio, Inc. (ACET)Healthcare | Biotechnology | Boston, United States | NasdaqCM
9.06 USD
+0.05
(0.555%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.06 |
Hot Take ↕ | Aug. 22, 2026, 1:58 a.m. EDT
This biotech stock presents a catastrophic long-term outlook despite a veneer of aggressive analyst optimism. The company has endured a brutal seven-year decline, erasing over 99% of its value, with the last three years showing consecutive negative annual returns. Fundamentals are broken: negative earnings, massive cash burn, and a balance sheet that cannot support the current valuation without immediate capital raises. The 'strong buy' analyst ratings appear disconnected from the reality of a failing business model. Short-term, the stock is range-bound and oversold, offering a speculative entry for traders willing to gamble on a catalyst, but the lack of dividends and deteriorating trajectory make it a dangerous hold for any investor seeking capital preservation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.107134 |
| AutoETS | 0.114488 |
| AutoARIMA | 0.114495 |
| AutoTheta | 0.209304 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.736 |
| Excess Kurtosis | -0.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.699 |
| Market Cap | 84,815,104 |
| Forward P/E | -2.29 |
| Beta | 1.59 |
| Website | https://www.adicetbio.com |
As of Aug. 22, 2026, 1:58 a.m. EDT: Speculators are positioning defensively with heavy put volume at the $7.50 strike, while call activity remains sparse and concentrated near the money. The implied volatility skew shows significantly higher pricing for downside protection compared to upside potential, suggesting a market consensus focused on avoiding further losses rather than anticipating a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.23279971 |
| Address1 | 131 Dartmouth Street |
| Address2 | 3rd Floor |
| All Time High | 2,362.864 |
| All Time Low | 6.01 |
| Ask | 11.25 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 99,630 |
| Average Daily Volume3 Month | 90,472 |
| Average Volume | 90,472 |
| Average Volume10Days | 99,630 |
| Beta | 1.594 |
| Bid | 6.48 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 11.161 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.06 |
| Current Ratio | 6.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 9.245 |
| Day Low | 8.76 |
| Debt To Equity | 10.699 |
| Display Name | Adicet Bio |
| Dividend Date | 1,600,214,400 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -98,121,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.08 |
| Enterprise Value | -7,811,233 |
| Eps Current Year | -6.396 |
| Eps Forward | -3.95 |
| Eps Trailing Twelve Months | -10.46 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.5812 |
| Fifty Day Average Change | 0.47880077 |
| Fifty Day Average Change Percent | 0.055796485 |
| Fifty Two Week Change Percent | -23.27997 |
| Fifty Two Week High | 17.44 |
| Fifty Two Week High Change | -8.38 |
| Fifty Two Week High Change Percent | -0.48050457 |
| Fifty Two Week Low | 6.01 |
| Fifty Two Week Low Change | 3.0500002 |
| Fifty Two Week Low Change Percent | 0.50748754 |
| Fifty Two Week Range | 6.01 - 17.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,516,977,000,000 |
| Float Shares | 7,439,116 |
| Forward Eps | -3.95 |
| Forward P E | -2.293671 |
| Free Cashflow | -47,516,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 102 |
| Fullday Change | 0.0500002 |
| Fullday Change Percent | 0.554941 |
| Fullday Price | 9.06 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.010779999 |
| Held Percent Institutions | 0.64912003 |
| Implied Shares Outstanding | 9,361,490 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,052,800 |
| Last Split Factor | 1:16 |
| Long Business Summary | Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts. |
| Long Name | Adicet Bio, Inc. |
| Market | us_market |
| Market Cap | 84,815,104 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_310073311 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -98,974,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 84,347,024 |
| Number Of Analyst Opinions | 6 |
| Open | 9.22 |
| Operating Cashflow | -84,529,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 503 9095 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 9.06 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 9.01 |
| Price Eps Current Year | -1.4165105 |
| Price Hint | 2 |
| Price To Book | 0.81175524 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.59 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0500002 |
| Regular Market Change Percent | 0.554941 |
| Regular Market Day High | 9.245 |
| Regular Market Day Low | 8.76 |
| Regular Market Day Range | 8.76 - 9.245 |
| Regular Market Open | 9.22 |
| Regular Market Previous Close | 9.01 |
| Regular Market Price | 9.06 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 111,284 |
| Return On Assets | -0.41665 |
| Return On Equity | -0.78083 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 9,361,490 |
| Shares Percent Shares Out | 0.027999999 |
| Shares Short | 262,357 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 383,174 |
| Short Name | Adicet Bio, Inc. |
| Short Percent Of Float | 0.028099999 |
| Short Ratio | 2.96 |
| Source Interval | 15 |
| State | MA |
| Symbol | ACET |
| Target High Price | 90.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 33.16667 |
| Target Median Price | 22.5 |
| Total Cash | 118,190,000 |
| Total Cash Per Share | 10.98 |
| Total Debt | 12,854,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.10563 |
| Two Hundred Day Average Change | 0.9543705 |
| Two Hundred Day Average Change Percent | 0.11774168 |
| Type Disp | Equity |
| Volume | 111,284 |
| Website | https://www.adicetbio.com |
| Zip | 2,116 |